Continuing Education Activity
Transient tachypnea of the newborn (TTN) is a benign, self-limited condition that can present in infants of any gestational age shortly after birth. It is caused by a delay in the clearance of fetal lung fluid after birth, which leads to ineffective gas exchange, respiratory distress, and tachypnea. It often poses a significant, diagnostic dilemma in the care of newborn babies with respiratory distress. This activity reviews the evaluation and management of transient tachypnea of the newborn and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.
Objectives:
Describe the risk factors for transient tachypnea of the newborn.
Describe the presentation of an infant with transient tachypnea of the newborn.
Describe the management of transient tachypnea of the newborn.
Explain the importance of improving coordination amongst the interprofessional team to enhance care for patients affected by transient tachypnea of the newborn.
Introduction
Transient tachypnea of the newborn (TTN) is a benign, self-limited condition that can present in infants of any gestational age, shortly after birth. It is caused due to delay in clearance of fetal lung fluid after birth which leads to ineffective gas exchange, respiratory distress, and tachypnea. In the nursery, it often poses a significant, diagnostic dilemma in the care of newborn babies with respiratory distress.
Etiology
Maternal risk factors include delivery before completion of 39 weeks gestation, a cesarean section without labor,gestational diabetes, and maternal asthma.[1][2]
Fetal risk factors include male gender, perinatal asphyxia, prematurity, small for gestational age, and large for gestational age infants.[3]
Epidemiology
Incidence is inversely proportional to gestation age and affects approximately 10% of infants delivered between 33 and 34 weeks, approximately 5% between 35 and 36 weeks, andless than 1% in term infants.[4][5][6]
Pathophysiology
Fetal Lung
The fetal pulmonary epithelium secretes alveolar fluid at around 6 weeks of gestation.[7]
Chloride ions in the interstitium enter the pulmonary epithelial cell through the active transport of sodium, potassium, and chloride into cells (Na-K-2Cl transporter) which, in turn, are secreted into the alveolus through various chloride channels.
Sodium follows the chloride ions through para-cellular pathways, and water is transported across the cells via aquaporin.[8][9]
Volumeoffetallung is maintained by the larynx, which acts as a one-way valve, allowing only outflow of fluid.
Neonatal Lung
Passive movement of sodium through epithelial sodium channels (ENaC) is believed to be the principle mechanism of reabsorption of fetal lung fluid with starling forces and thoracic squeeze playing a minor role in clearance.
With the onset of labor, maternal epinephrine,[10] and glucocorticoids activate the ENaC on the apical membranes of type II pneumocytes.
Sodium in the alveolus is transported passively across the ENaC proteins which in turnis actively transported back to the interstitium by the Na+/K+-ATPase pump.[11]
An osmotic gradient is created which allows chloride and water to follow and be absorbed into pulmonary circulation and lymphatics.
History and Physical
The conditionpresents within the first few minutes to hours after birth.
Physical exam findings usually include signs of respiratory distress:
Tachypnea (respiratory rate greater than 60 per minute)
Nasal flaring
Grunting[12]
Intercostal/subcostal/suprasternal retractions
Crackles, diminished or normal breath sounds on auscultation
Other occasional exam findings:
Tachycardia
Cyanosis
Barrel-shaped chest because of hyperinflation
Evaluation
Duration of respiratory distress is the principal determinant for diagnosis of TTN. If distress resolves within the first few hours of birth, it can be labeled as "delayed transition." Six hours is an arbitrary cutoff between "delayed transition" and TTN because by this time baby might develop issues with feeding and might require further interventions. TTN is usually a diagnosis of exclusion and hence any tachypnea lasting over 6 hours requires workup to rule out other causes of respiratory distress.
The workup usually includes:
Preductal and postductal saturations: to rule out differential cyanosis
Complete blood count (CBC), blood culture, C-reactive protein (CRP), lactate to rule out neonatal sepsis
ABG analysis may show hypoxemia and hypocapnia due to tachypnea; hypercapnia is a sign of fatigue or air leak.
Chest x-ray: May show hyperinflation, prominent perihilar vascular markings, edema of interlobar septae or fluid in the fissures.[13][14]
Other workups to consider:
Ammonia level in the setting of lethargy and metabolic acidosis to rule out inborn errors of metabolism
Echocardiography to rule out congenital cardiac defects in patients with differential cyanosis or persistent tachypnea for over 4 to 5 days
Treatment / Management
Given TTN is a self-limited condition, supportive care is the mainstay of treatment.
Rule of 2 hours: Two hours after onset of respiratory distress, if an infant’s condition has not improved or hasworsened or if FiO2 required is more than 0.4 or chest x-ray is abnormal, consider transferring infant to a center with a higher level of neonatal care.[15]
Routine NICU care including continuous cardiopulmonary monitoring, maintenance of neutral thermal environment, securing intravenous (IV)access, blood glucose checks, and observation for sepsis should be provided.
Respiratory
Oxygen support may be required if pulse oximetry or ABG suggest hypoxemia.
An oxygen hood is the preferred initial method; however, nasal cannula, CPAP can also be used.
Concentration should be adjusted to maintain oxygen saturation in low 90s.
Endotracheal intubation and requirement of ECMO support is usually uncommon but should always be considered in patients with declining respiratory status.
Arterial blood gas (ABG) analysis should be repeated, and pulse oximetry monitoring should be continued until signs of respiratory distress have resolved.
Nutrition
Neonates’ respiratory status is the usual determinant for the degree of nutritional support required.
Tachypnea of over 80 breaths per minute with associated increased work of breathing often makes it unsafe for the infant to receive oral feeds.
Such infants should be kept nil per oral (NPO), and intravenous (IV) fluids should be started at 60 to 80 ml per kg per day.
If respiratory distress is resolving, diagnosis is certain and respiratory rate is less than 80 breaths per minute; enteral feeds can be started.
Enteral feeds should always be started slowly with progressive increments in volume of feeds until tachypnea has completely resolved
Infectious
Since TTN may be difficult to distinguish from early neonatal sepsis and pneumonia, empiric antibiotic therapy with ampicillin and gentamicin should always be considered.
Medications
Randomized control trials studying the efficacy of furosemide[16]or racemic epinephrine[17]in TTN showed no significant difference in duration of tachypnea or length of hospital stay compared with controls
Salbutamol (inhaled beta2-agonist) has been shown to decrease the duration of symptoms and hospital stay; however, more evidence-based studies are needed to confirm its efficacy and safety.[18][19]
Differential Diagnosis
Pneumonia
Respiratory distress syndrome
Aspiration syndromes: meconium, blood or amniotic fluid
Pneumothorax
Left-to-right cardiac shunt defects with failure
Persistent pulmonary hypertension
Central nervous system (CNS) irritation or disease: Subarachnoid hemorrhage, hypoxic-ischemic encephalopathy
Inborn errors of metabolism
Congenital malformations: Congenital diaphragmatic hernia, cystic adenomatoid malformations
Prognosis
Overall prognosis is excellent with most of the symptoms resolving within 48 hours of onset.
In some case reports, malignant TTN has been reported in which affected newborns develop persistent pulmonary hypertension due to a possible elevation of pulmonary vascular resistance due to retained lung fluid.[20]
Complications
Air leaks and pneumothoraces are other rare complications.
Longitudinal studies have shown an association between TTN and subsequent development of asthma.[21][22]
Pearls and Other Issues
What is transient tachypnea of the newborn?
Transient tachypnea of the newborn (TTN) is a condition that causes breathing problems in newborn babies. Babies have fluid in their lungs before birth. The fluid normally goes away when a baby is born. In some babies, the fluid does not go away as quickly as it should. This causes TTN.
A mother who has diabetes, asthma, or a C-section without labor is more likely to have a baby with TTN.
What are the symptoms of TTN?
Fast breathing of more than 60 breaths a minute
Hard breathing: Nostrils that open wide when the baby takes a breath, skin, and muscles that look like they are caving in; grunting
How is TTN treated?
TTN usually goes away by the time a baby is 3 days old. Until that happens, doctors can help the baby get enough oxygen and nutrition if he or she needs it. Treatments might include:
Extra oxygen
An intravenous (IV) feeding tube
Antibiotics
Enhancing Healthcare Team Outcomes
Transient tachypnea of the newborn is a common condition seen in newborn babies. Healthcare workers including intensive care nurses need to know thatthe cause is due to fluid accumulation in the lungs. The condition is usually managedby an interprofessional team as there are many disorders which can present with similar symptoms. The condition, once diagnosed, is treated conservatively with oxygen, antibiotics, and sometimes with the use of a diuretic. The prognosis for most infants is excellent.
Review Questions
References
- 1.
Badran EF, Abdalgani MM, Al-Lawama MA, Al-Ammouri IA, Basha AS, Al Kazaleh FA, Saleh SS, Al-Katib FA, Khader YS. Effects of perinatal risk factors on common neonatal respiratory morbidities beyond 36 weeks of gestation. Saudi Med J. 2012 Dec;33(12):1317-23. [PubMed: 23232680]
- 2.
Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol. 1995 Feb;102(2):101-6. [PubMed: 7756199]
- 3.
Dani C, Reali MF, Bertini G, Wiechmann L, Spagnolo A, Tangucci M, Rubaltelli FF. Risk factors for the development of respiratory distress syndrome and transient tachypnoea in newborn infants. Italian Group of Neonatal Pneumology. Eur Respir J. 1999 Jul;14(1):155-9. [PubMed: 10489844]
- 4.
Zanardo V, Simbi AK, Franzoi M, Soldà G, Salvadori A, Trevisanuto D. Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr. 2004 May;93(5):643-7. [PubMed: 15174788]
- 5.
Kasap B, Duman N, Ozer E, Tatli M, Kumral A, Ozkan H. Transient tachypnea of the newborn: predictive factor for prolonged tachypnea. Pediatr Int. 2008 Feb;50(1):81-4. [PubMed: 18279211]
- 6.
Jain L. Respiratory morbidity in late-preterm infants: prevention is better than cure! Am J Perinatol. 2008 Feb;25(2):75-8. [PubMed: 18214813]
- 7.
Guglani L, Lakshminrusimha S, Ryan RM. Transient tachypnea of the newborn. Pediatr Rev. 2008 Nov;29(11):e59-65. [PubMed: 18977854]
- 8.
Strang LB. Fetal lung liquid: secretion and reabsorption. Physiol Rev. 1991 Oct;71(4):991-1016. [PubMed: 1924552]
- 9.
Adamson TM, Brodecky V, Lambert TF, Maloney JE, Ritchie BC, Walker AM. Lung liquid production and composition in the "in utero" foetal lamb. Aust J Exp Biol Med Sci. 1975 Feb;53(1):65-75. [PubMed: 1147855]
- 10.
Brown MJ, Olver RE, Ramsden CA, Strang LB, Walters DV. Effects of adrenaline and of spontaneous labour on the secretion and absorption of lung liquid in the fetal lamb. J Physiol. 1983 Nov;344:137-52. [PMC free article: PMC1193830] [PubMed: 6655575]
- 11.
Jain L. Alveolar fluid clearance in developing lungs and its role in neonatal transition. Clin Perinatol. 1999 Sep;26(3):585-99. [PubMed: 10494466]
- 12.
Yost GC, Young PC, Buchi KF. Significance of grunting respirations in infants admitted to a well-baby nursery. Arch Pediatr Adolesc Med. 2001 Mar;155(3):372-5. [PubMed: 11231804]
- 13.
Cleveland RH. A radiologic update on medical diseases of the newborn chest. Pediatr Radiol. 1995;25(8):631-7. [PubMed: 8570317]
- 14.
Kurl S, Heinonen KM, Kiekara O. The first chest radiograph in neonates exhibiting respiratory distress at birth. Clin Pediatr (Phila). 1997 May;36(5):285-9. [PubMed: 9152555]
- 15.
Hein HA, Ely JW, Lofgren MA. Neonatal respiratory distress in the community hospital: when to transport, when to keep. J Fam Pract. 1998 Apr;46(4):284-9. [PubMed: 9564369]
- 16.
Kassab M, Khriesat WM, Anabrees J. Diuretics for transient tachypnoea of the newborn. Cochrane Database Syst Rev. 2015 Nov 21;2015(11):CD003064. [PMC free article: PMC7144734] [PubMed: 26590358]
- 17.
Kao B, Stewart de Ramirez SA, Belfort MB, Hansen A. Inhaled epinephrine for the treatment of transient tachypnea of the newborn. J Perinatol. 2008 Mar;28(3):205-10. [PubMed: 18200024]
- 18.
Armangil D, Yurdakök M, Korkmaz A, Yiğit S, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr. 2011 Sep;159(3):398-403.e1. [PubMed: 21481414]
- 19.
Kim MJ, Yoo JH, Jung JA, Byun SY. The effects of inhaled albuterol in transient tachypnea of the newborn. Allergy Asthma Immunol Res. 2014 Mar;6(2):126-30. [PMC free article: PMC3936040] [PubMed: 24587948]
- 20.
Lakshminrusimha S, Keszler M. Persistent Pulmonary Hypertension of the Newborn. Neoreviews. 2015 Dec;16(12):e680-e692. [PMC free article: PMC4714607] [PubMed: 26783388]
- 21.
Schaubel D, Johansen H, Dutta M, Desmeules M, Becker A, Mao Y. Neonatal characteristics as risk factors for preschool asthma. J Asthma. 1996;33(4):255-64. [PubMed: 8707780]
- 22.
Birnkrant DJ, Picone C, Markowitz W, El Khwad M, Shen WH, Tafari N. Association of transient tachypnea of the newborn and childhood asthma. Pediatr Pulmonol. 2006 Oct;41(10):978-84. [PubMed: 16871596]
Disclosure: Kanishk Jha declares no relevant financial relationships with ineligible companies.
Disclosure: George Nassar declares no relevant financial relationships with ineligible companies.
Disclosure: Kartikeya Makker declares no relevant financial relationships with ineligible companies.